A novel polyrotaxane-based intracellular delivery system for camptothecin: In vitro feasibility evaluation

Journal of Biomedical Materials Research - Part A

Volumn 84, Issue 1, 2008, Pages 238-246

  Moon, Cheol ^a,b   Young, Min Kwon ^b   Won, Kyu Lee ^c   Yoon, Jeong Park ^d   Chang, Li Chien ^e   Yang, Victor C ^a,b  

^a TIANJIN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Korea Drug and Food Administration   (South Korea)

^d School of Dentistry   (South Korea)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Camptothecin; Heparin inhibition; Low molecular weight protamine; Polyrotaxane

Indexed keywords

ANTITUMOR ACTIVITY; CAMPTOTHECIN; FEASIBILITY EVALUATION; HEPARIN INHIBITION; POLYROTAXANE;

ANTIBIOTICS; BIOASSAY; CELLS; MOLECULAR WEIGHT; ONCOLOGY; TUMORS;

DRUG DELIVERY;

CAMPTOTHECIN; CELL PENETRATING PEPTIDE; HEPARIN; POLYROTAXANE; PROTAMINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; FEASIBILITY STUDY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; OVARY CANCER;

CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CYCLODEXTRINS; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FLOW CYTOMETRY; HEPARIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; POLOXAMER; PROTAMINES; ROTAXANES;

EID: 36949025736     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31452     Document Type: Article

References (21)

1. Wall ME, Wani MC, Cook CE, Palmar KH, McPhail AT, Sim GA. Plant tumor agent. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibition from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-3890.
2. Kingsbery WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher MJ, Caranfa FL, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP. Synthesis of water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;31:98-107.
3. Takimoto CH, Arbuck SG. Topoisomerase I Targeting Agent: The Camptothecins. Philadelphia:Lippincott Williams & Wilkins; 2001. p 579-646.
4. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumori-tropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12, Part 1):6387-6392.
5. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
6. Minko T, Kopeckova P, Kopecek J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res 1999;16:986-996.
7. Yui N. New world of micromachines based on supramolecular assemblies. Micromachine 1999;29:3-4.
8. Ichi T, Watanabe J, Ooya T, Yui N. Controllable erosion time and profile in poly(ethylene glycol) hydrogels by supramolecular structure of hydrolyzable polyrotaxane. Biomacromolecules 2001;2:204-210.
9. Ooya T, Yui N. Polyrotaxanes: Synthesis, structure, and potential in drug delivery. Crit Rev Ther Drug Carrier Syst 1999;16:289-330.
10. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999;285:1569-1572.
11. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpes virus structural protein. Cell 1997;88:223-233.
12. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991;88:1864-1868.
13. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002;277:2437-2443.
14. Chang LC, Lee HF, Yang Z, Yang VC. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): Preparation and characterization. AAPS Pharm Sci 2001;3:E17.
15. Chang LC, Liang JF, Lee HF, Lee LM, Yang VC. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity. AAPS PharmSci 2001;3:E18.
16. Lee LM, Chang LC, Wrobleski S, Wakefield TW, Yang VC. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci 2001;3:E19.
17. Park YJ, Chang LC, Liang JF, Moon C, Chung CP, Yang VC. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: In vitro and in vivo study. FASEB J 2005;19:1555-1557.
18. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: The Trojan horse approach. Mol Cell Neurosci 2004;27:85-131.
19. Harada A, Kamachi M. Complex formation between poly (ethylene glycol) and a-cyclodextrin. Macromolecules 1990;23:2821-2823.
20. Han G, Tamaki M, Hruby VJ. Fast, efficient and selective deprotection of the tert-butoxycarbonyl (Boc) group using HCl/dioxane (4 m). J Pept Res 2001;58:338-341.
21. Singer JW, Bhatt R, Tulinsky J, Buhler KR, Heasley E, Klein P, de Vries P. Water-soluble poly(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74:243-247.